Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gregory A Otterson

Showing results (101-110 of 157) with videos related to

Pageof 16
Sort By:
Cancer Immunology, Immunotherapy : CII|July 31, 2020
Brief report: inhaled corticosteroid use and the risk of checkpoint inhibitor pneumonitis in patients with advanced cancerMingjia Li, Daniel Spakowicz, Songzhu Zhao, et al.
The Oncologist|April 21, 2023
Risk Factors for Immune Checkpoint Inhibitor Immunotherapy Toxicity Among Older Adults with CancerAndrew C Johns, Mike Yang, Lai Wei, et al.
Oncogene|April 30, 2004
Bone morphogenetic protein 3B silencing in non-small-cell lung cancerZunyan Dai, Anthony P Popkie, Wei-Guo Zhu, et al.
JAMA Oncology|October 29, 2020
Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung CancerBairavi Shankar, Jiajia Zhang, Abdul Rafeh Naqash, et al.
Journal of Cancer Research and Clinical Oncology|September 7, 2022
Immune checkpoint inhibitor-induced hepatitis injury: risk factors, outcomes, and impact on survivalAbdul Miah, Gabriel Tinoco, Songzhu Zhao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 5, 2019
Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated ColitisHamzah Abu-Sbeih, Faisal S Ali, Abdul Rafeh Naqash, et al.
Cancer Immunology, Immunotherapy : CII|March 7, 2020
Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohortAbdul Rafeh Naqash, Biagio Ricciuti, Dwight H Owen, et al.
Cancer Immunology, Immunotherapy : CII|April 30, 2020
Correction to: Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohortAbdul Rafeh Naqash, Biagio Ricciuti, Dwight H Owen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 16, 2009
Phase I active immunotherapy with combination of two chimeric, human epidermal growth factor receptor 2, B-cell epitopes fused to a promiscuous T-cell epitope in patients with metastatic and/or recurrent solid tumorsPravin T P Kaumaya, Kevin Chu Foy, Joan Garrett, et al.
Oncoimmunology|February 21, 2025
Evaluating the effect of immune checkpoint inhibitor treatment on chronic obstructive pulmonary disease in lung cancer patientsAnet Greib, Songzhu Zhao, Michelle Ploch, et al.
Pageof 16

Showing results (101-110 of 157) with videos related to

Sort By:
Pageof 16
Cancer Immunology, Immunotherapy : CII|July 31, 2020
Brief report: inhaled corticosteroid use and the risk of checkpoint inhibitor pneumonitis in patients with advanced cancerMingjia Li, Daniel Spakowicz, Songzhu Zhao, et al.
The Oncologist|April 21, 2023
Risk Factors for Immune Checkpoint Inhibitor Immunotherapy Toxicity Among Older Adults with CancerAndrew C Johns, Mike Yang, Lai Wei, et al.
Oncogene|April 30, 2004
Bone morphogenetic protein 3B silencing in non-small-cell lung cancerZunyan Dai, Anthony P Popkie, Wei-Guo Zhu, et al.
JAMA Oncology|October 29, 2020
Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung CancerBairavi Shankar, Jiajia Zhang, Abdul Rafeh Naqash, et al.
Journal of Cancer Research and Clinical Oncology|September 7, 2022
Immune checkpoint inhibitor-induced hepatitis injury: risk factors, outcomes, and impact on survivalAbdul Miah, Gabriel Tinoco, Songzhu Zhao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 5, 2019
Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated ColitisHamzah Abu-Sbeih, Faisal S Ali, Abdul Rafeh Naqash, et al.
Cancer Immunology, Immunotherapy : CII|March 7, 2020
Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohortAbdul Rafeh Naqash, Biagio Ricciuti, Dwight H Owen, et al.
Cancer Immunology, Immunotherapy : CII|April 30, 2020
Correction to: Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohortAbdul Rafeh Naqash, Biagio Ricciuti, Dwight H Owen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 16, 2009
Phase I active immunotherapy with combination of two chimeric, human epidermal growth factor receptor 2, B-cell epitopes fused to a promiscuous T-cell epitope in patients with metastatic and/or recurrent solid tumorsPravin T P Kaumaya, Kevin Chu Foy, Joan Garrett, et al.
Oncoimmunology|February 21, 2025
Evaluating the effect of immune checkpoint inhibitor treatment on chronic obstructive pulmonary disease in lung cancer patientsAnet Greib, Songzhu Zhao, Michelle Ploch, et al.
Pageof 16